Revance Therapeutics, Inc. (RVNC)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-market:
| Previous close | 4.2700 |
| Open | 4.3100 |
| Bid | 4.2800 x 1100 |
| Ask | 4.3100 x 700 |
| Day's range | 4.2501 - 4.4750 |
| 52-week range | 3.2100 - 35.8300 |
| Volume | |
| Avg. volume | 1,846,272 |
| Market cap | 447.087M |
| Beta (5Y monthly) | 1.15 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Lags Revenue Estimates
Revance Therapeutics (RVNC) delivered earnings and revenue surprises of 18.18% and 6.66%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
Revance Therapeutics, Inc. (NASDAQ:RVNC) is favoured by institutional owners who hold 63% of the company
Key Insights Institutions' substantial holdings in Revance Therapeutics implies that they have significant influence...
- Insider Monkey
Revance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2023 Earnings Call Transcript
Revance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2023 Earnings Call Transcript February 29, 2024 Revance Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the Revance Therapeutics Fourth Quarter and Full Year 2023 Financial Results and Corporate Update Conference […]
© 2024 Yahoo. All rights reserved.